Cegedim SA (EPA:ALCGM)
France
· Delayed Price · Currency is EUR 10.05
-0.10 (-0.99%)
Mar 9, 2026, 5:39 PM CET
Cegedim Revenue
Cegedim had revenue of 322.50M EUR in the half year ending June 30, 2025, with 7.14% growth. This brings the company's revenue in the last twelve months to 658.00M, up 3.79% year-over-year. In the year 2024, Cegedim had annual revenue of 654.50M with 6.25% growth.
Revenue (ttm)
658.00M
Revenue Growth
+3.79%
P/S Ratio
0.21
Revenue / Employee
99.62K
Employees
6,605
Market Cap
138.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 654.50M | 38.50M | 6.25% |
| Dec 31, 2023 | 616.00M | 60.79M | 10.95% |
| Dec 31, 2022 | 555.21M | 30.50M | 5.81% |
| Dec 31, 2021 | 524.71M | 27.77M | 5.59% |
| Dec 31, 2020 | 496.94M | -6.81M | -1.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 28.49B |
| Sanofi | 46.72B |
| Sartorius Stedim Biotech | 2.97B |
| Ipsen | 3.93B |
| Guerbet | 820.92M |
| Euroapi | 852.60M |
| Innate Pharma | 12.64M |
| MaaT Pharma | 3.92M |
Cegedim News
- 4 months ago - Half Year 2025 Cegedim SA Earnings Call Transcript - GuruFocus
- 5 months ago - Cegedim's profitability improving as expected in H1 2025 - Benzinga